By Kuldip K. Ambastha
On Thursday, January 5, 2023, the stock of NovoCure Limited (NVCR), an oncology company, rose by +68.5% for the trading day. The LUNAR study has shown that a medical device developed by NovoCure is able to improve, in a statistically significant way, the prospect of survival for people with late-stage lung cancer. Thus, the company’s Tumor Treating Fields therapy is very promising. That said, the full study results are not yet available but NovoCure hopes to release a complete data set on this front in the near future at a medical conference. After the full study results are known and the needed regulatory approvals are obtained around the world, NovoCure may be able to expand its patient pipeline significantly.
Keywords – NovoCure Limited, NovoCure, NVCR, lung cancer, medical device, LUNAR study, Tumor Treating Fields therapy, study, data, regulation, approval, patients.
Disclosure – The principals and clients of Ambastha Financial LLC have no positions in NVCR.
Disclaimer – No recommendations are being made via this post. Past performance is not an indicator of future performance. As an investor, you should do your own research and seek professional advice from a Registered Investment Adviser (RIA). You can lose money by investing in stocks and other instruments. Ambastha Financial LLC does not assume any responsibility (legal or otherwise) for any losses that may occur as a result of actions taken based on this post. All content copyrighted © 2023 – Ambastha Financial LLC.
CONTACT US